Regeneron Pharmaceuticals, Inc. (REGN)

From the record

Regeneron Pharmaceuticals, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Regeneron Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $4.9 billion in fiscal 2016 to $14 billion in fiscal 2025, up 12.8% a year; it rose in 7 of 9 years; the deepest fall was 24% from fiscal 2021 to fiscal 2022; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Regeneron Pharmaceuticals, Inc.'s diluted share count shrank about 1.5% a year, and dividends and buybacks returned about 62% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 135 sales (107 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-06 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Regeneron Pharmaceuticals, Inc. earned about 14 cents of profit for every dollar of shareholders' money. Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count shrank 5.6% over the year (the filed statements).

From the record

Regeneron Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $14 billion in fiscal 2025 ranks in the top 4% by size; a net margin of 31.4% ranks in the top 9%; revenue growth of 5.6% a year over the last 3 filed years ranks in the bottom 48% (its annual reports).

From the record

Regeneron Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Schleifer, Leonard S (Bd. Co-Chair, President & CEO, as filed), filing under that title since 2006-03-08, 20.7 years (top 1% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 10.2 years (top 8%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (top 7%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Regeneron Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3.1 billion against debt of $2.0 billion leaves 2.8% of its assets as net cash, bottom 16% of its family; cash from operations less capital spending is 28.4% of revenue (top 8%); research spending of 40.8% of revenue (bottom 39%) (its annual report).

From the record

Regeneron Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 5.6% a year over the last three filed years against 12.8% over all 10, slowing (bottom 40% of its family); the newest year grew 1% (bottom 41%); research spending grew 17.6% a year (top 26%); capital spending grew 15% a year (top 27%) (its annual reports). Regeneron Pharmaceuticals, Inc. reported 4 product lines in fiscal 2025: Collaboration Revenue at $7.3 billion (51%), Product at $6.3 billion (44%), Product and Service Other at $703 million (5%), and 1 more; 2 of 3 grew against the year before (its annual report).

From the record

Regeneron Pharmaceuticals, Inc.'s newest year against its own record: revenue of $14 billion in fiscal 2025 came in 6.5% below the $15 billion its prior three years' pace pointed to (bottom 43% of its family); net income of $4.5 billion against a prior three-year average of $4.2 billion (bottom 44%); a net margin of 31.4% against 32.3% before (bottom 35%) (its annual reports).